Table 6.
Phytochemical | Lipid-based formulation | Effect of formulation | Admin. route | Ref. | |
---|---|---|---|---|---|
Type | Subcategory | ||||
Curcumin | LBDS | NLCs | Enhanced stability and brain targeting in vivo. | Intraperitoneal | [353] |
Baicalein | LBDS | Tocol-NLCs | [354] | ||
β-Elemene | NLCs | Less irritating and toxic and enhanced bioavailability and antitumor efficacy in vivo. | [355] | ||
Bufadienolides | Reduced toxicity and improved pharmacokinetic profile in vivo. | Intravenous | [356] | ||
Breviscapine | Ionic-complex-based NLCs | Sustained-release and protection against liver enzyme degradation in vivo. | [357] | ||
Berberine | DQA-PEG2000-DSPEa liposomes | Overcome multidrug resistance in vivo. | [358] | ||
| |||||
Quercetin | LBDS | MEs | Transdermal | [158] | |
Genistein | Increased permeation and skin retention. | [159] | |||
Chlorogenic acid | Efficient systemic distribution in vivo. | [160] | |||
Resveratrol | |||||
Curcumin | PEGa liposomes | Increased stability and anti-inflammatory effects in vivo | [359] | ||
Bufadienolides | Poloxamer-liposomes | Reduced toxicity and enhanced antitumor efficacy in vivo. | [360] | ||
Ligustrazine phosp. | Ethosomes | Enhanced skin permeation in vitro and bioactivity in vivo. | [152] | ||
Apigenin | Enhanced anti-inflammatory effects in vivo. | [361] | |||
Curcumin | NLCs | Enhanced antitumor activity and brain targeting in vitro. | Intranasal | [362] | |
Tetrandrine | Charged SLNs | Reduced irritation of eye mucous membrane in vivo. | Ocular | [363] | |
| |||||
3-ECGC | Inorganic carriers | Gold NPs | Enhanced efficacy and reduced toxicity in vivo. | Intratumoral injection | [155] |
| |||||
Curcumin | PBDS | Dextran sulfate-chitosan NPs | Controlled release and targeted effect against tumor cells in vitro. | Intravenous | [364] |
Curcumin | Chitosan/PBCAb NPs | In vivo anticancer effect on hepatic tumor cells. | [365] | ||
Trans-resveratrol | Chitosan-NPs | Higher in vivo liver targeting effect and in vitro cytotoxicity on hepatic cancer cells. | [366–368] | ||
Oridonin | Galactosylated chitosan NPs | Enhanced targeting and binding to the specific site of action (liver). | |||
| |||||
Artemisinin | PBDS | Polymeric micelles Targeted polymeric micelles |
Achieving site-specific cell targeting and enhancing intracellular drug accumulation. | Intraperitoneal | [369] |
Resveratrol | Transferrin modified PEG-PLAc conjugate | Cellular uptake, in vivo biodistribution, and antitumor activity. Targeted therapy of glioma. | [370] | ||
Bufalin | Biotinylated chitosan NPs | Enhanced targeting and binding to the specific site of action breast carcinoma. | [371] | ||
| |||||
Quercetin | PBDS | Lecithin-chitosan NPs | In vitro and in vivo enhanced skin permeation. | Topical | [371] |
aPEG: polyethylene glycol; DQA: dequalinium; DSPE: polyethylene glycol-distearoylphosphatidylethanolamine.
bPBCA: poly(butyl cyanoacrylate).
cPLA: polylactic acid.